Quest Diagnostics Inc. (DGX) is a publicly traded Healthcare sector company. As of July 8, 2026, DGX trades at $208.80 with a market cap of $23.63B and a P/E ratio of 23.30. DGX moved -1.62% today. Year to date, DGX is +21.02%; over the trailing twelve months it is +22.08%. Its 52-week range spans $148.70 to $219.20. Analyst consensus is buy with an average price target of $223.13. Rallies surfaces DGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Quest Diagnostics Integrates Haystack MRD into OncoEMR for 4,700 Clinicians: Quest Diagnostics is integrating its Haystack MRD ctDNA test and Comprehensive Genomic Profiling services into Flatiron Health’s OncoEMR via a pilot with American Oncology Network. The integration will enable 4,700 clinicians at 1,600 sites to order tests with fewer steps and receive results within their EHR workflows.
| Metric | Value |
|---|---|
| Price | $208.80 |
| Market Cap | $23.63B |
| P/E Ratio | 23.30 |
| EPS | $9.17 |
| Dividend Yield | 0.86% |
| 52-Week High | $219.20 |
| 52-Week Low | $148.70 |
| Volume | 175.96K |
| Avg Volume | 0 |
| Revenue (TTM) | $11.28B |
| Net Income | $1.07B |
| Gross Margin | 33.20% |
10 analysts cover DGX: 0 strong buy, 5 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $223.13.